

References

I-83

1. Ishitsuka K, Utsunomiya A, Katsuya H, et al. A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma. *Cancer Sci*. 2015;1219-1223.
2. Sullivan RJ, Ibrahim N, Lawrence DP, et al. A phase I trial of bortezomib and sorafenib in advanced malignant melanoma. *The Oncologist*. 2015;617-618.
3. Lee J, Kim BS, Park Y et al. The effect of bortezomib on antibody-mediated rejection after kidney transplantation. *Yonsei Med J*. 2015;1638-1642.
4. National Comprehensive Cancer Network (NCCN). Drugs and Biologics Compendium. 2023. Bortezomib.
5. San Miguel J, Schlag R, Khuageva N, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone Versus melphalan-prednisone in patients with previously untreated multiple myeloma. *J Clin Oncol*. 2013;31(4);448-455.
6. Gimsing P, Hjertner O, Abildgaard N, et al. Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. *Bone Marrow Transplantation*. 2015;50:1306-1311.
7. Durie B, Hoering A, Abidi M, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *The Lancet*. 2017;389(10068):519-527.
8. Clinical Pharmacology Compendia™. Tampa FL: Gold Standard, Inc. Bortezomib. 2023.
9. Micromedex®Solutions Compendia. Bortezomib. 2023.
10. Bortezomib In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 6, 2018.
11. Mateos M, Dimopoulos M, Cavo M, et al. Daratumumab plus borteomib, melphalan, and prednisone for untreated myeloma. *N Engl J Med*. 2018;378:518-528.
12. Katritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan and dexamethasone for light-chain amyloidosis. *J Clin Oncol*. 2020;1-10.
13. Velcade® (Bortezomib) for injection, for subcutaneous or intravenous use [package insert]. Takeda Pharmaceuticals. Lexington, MA. Revised 08/2022.